BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study a

CRIS Contra el Cáncer financia una nueva estrategia de terapias dirigidas frente al cáncer de ovario

Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData

As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on

Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

Conditions : Metastatic Myxoid Liposarcoma; Metastatic Synovial Sarcoma; Unresectable Myxoid Liposarcoma; Unresectable Synovial Sarcoma Inte

A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Conditions : NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); NSCLC;

<![CDATA[Gedatolisib Approval in HR+/HER2- Breast Cancer May Be “Practice Changing”]]>